Arcus Biosciences
RCUS
24.52
+0.24
+0.99%
Arcus Biosciences
US · RCUS
#2467 by market cap
Listed 2018
24.52
+0.24
+0.99%
Live - 5344 symbols - heartbeat 244s ago
· 2026-10-07 19:54
After-hours
24.52
0.00%
- Market cap
- 3.12B
- P/E (TTM)i
- -6.22
- P/Bi
- 6.73
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on RCUS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 98.36% +0.06pp
- Institutions
- 289 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund49.24%
Public Company26.87%
Hedge Fund17.62%
Individual/Insider3.61%
VC/PE Fund2.76%
Private Company0.87%
Government Pension Fund0.77%
Insurance Company0.21%
Top holders as of 2026-08-05
Gilead Sciences, Inc.
24.68% · 31.42M sh
BlackRock
12.89% · 16.42M sh
State Street Global Advisors
4.74% · 6.03M sh
Wellington Management Group
4.63% · 5.90M sh
Montanova Capital, LLC
3.75% · 4.78M sh
Vanguard Capital Management, LLC
3.54% · 4.50M sh
Vanguard Portfolio Management, LLC
3.51% · 4.48M sh
FMR
3.18% · 4.05M sh
Citadel Advisors LLC
2.46% · 3.14M sh
Woodline Partners LP
2.36% · 3.01M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Gilead Sciences, Inc. | -- | 24.68% |
| Terry Rosen | Chairperson & CEO | 2.04% |
| Juan Jaen | Co-Founder & President | 0.86% |
| Yasunori Kaneko | Lead Independent Director | 0.15% |
| Kathryn Falberg | Independent Director | 0.13% |
| Jennifer Jarrett | Chief Operating Officer | 0.10% |
| Carolyn Tang | General Counsel | 0.09% |
| David Lacey | Independent Director & Member of Scientific Advisory Board | 0.06% |
| Antoni Ribas | Independent Director & Member of Scientific Advisory Board | 0.04% |
| Andrew Perlman | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-20 | Alexander Azoy | VP of Finance & Principal Accounting Officer | Derivative Exercise and Sale | -2,827 | $15.44–30.00 |
| 2026-07-09 | Juan Jaen | Co-Founder & President | Open Market Disposition | -68,569 | $28.61–30.05 |
| 2026-06-23 | Juan Jaen | Co-Founder & President | Automatic Disposition | -31,431 | $27.03–29.66 |
| 2026-06-10 | Yasunori Kaneko | Lead Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Kathryn Falberg | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Andrew Perlman | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | C. Machado | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-06-10 | David Lacey | Independent Director & Member of Scientific Advisory Board | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Antoni Ribas | Independent Director & Member of Scientific Advisory Board | Other Acquisition | +5,700 | -- |
| 2026-06-10 | Carolyn Tang | General Counsel | Derivative Exercise and Retained | +34,090 | $2.57 |
| 2026-06-10 | Nicole Lambert | Independent Director | Other Acquisition | +5,700 | -- |
| 2026-05-31 | Alexander Azoy | VP of Finance & Principal Accounting Officer | Automatic Disposition | -2,562 | $25.77 |
| 2026-05-10 | Robert Goeltz | Principal Financial Officer & CFO | Open Market Disposition | -7,763 | $25.63 |
| 2026-05-05 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -77,793 | $24.60 |
| 2026-04-22 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -53,826 | $25.20 |
| 2026-04-07 | Jennifer Jarrett | Chief Operating Officer | Intent to Sell (Form 144) | -70,000 | $22.57 |
| 2026-01-22 | Juan Jaen | Co-Founder & President | Other Acquisition | +31,000 | -- |
| 2026-01-22 | Juan Jaen | Co-Founder & President | Other Derivative Acquisition | +126,000 | $22.13 |
| 2026-01-22 | Robert Goeltz | Principal Financial Officer & CFO | Other Acquisition | +24,000 | -- |
| 2026-01-22 | Robert Goeltz | Principal Financial Officer & CFO | Other Derivative Acquisition | +96,000 | $22.13 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.